Fig. 3: Change in BCVA from baseline through to Week 96 in eyes with persistent retinal fluid. | Eye

Fig. 3: Change in BCVA from baseline through to Week 96 in eyes with persistent retinal fluid.

From: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies

Fig. 3

A BCVA changes in eyes with persistent IRF and/or SRF (aflibercept-treated eyes: n = 140; brolucizumab-treated eyes: n = 82); B BCVA changes in eyes with persistent SRF (with or without IRF; aflibercept-treated eyes: n = 87; brolucizumab-treated eyes: n = 36); C BCVA changes in eyes with persistent IRF (with or without SRF; aflibercept-treated eyes: n = 41; brolucizumab-treated eyes: n = 43). Analysed using ANOVA model with baseline BCVA categories (< = 55, 56–70, > = 71 letters), age categories (<75, ≥75 years) and treatment as fixed effect factors. ANOVA analysis of variance, BCVA best corrected visual acuity, ETDRS Early Treatment Diabetic Retinopathy Study, IRF intraretinal fluid, LS least squares, SE standard error; SRF subretinal fluid.

Back to article page